Wantai Biological Pharmacy reports net loss of 128 million yuan in 2026 interim report

Jiemian··CN·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Wantai Biological Pharmacy released its 2026 interim report, with net profit attributable to the parent company at minus 128 million yuan. Total operating revenue was 1.048 billion yuan, and net cash flow from operating activities was minus 81.32 million yuan, a decrease of 14.77 million yuan compared with the same period last year. The latest asset-liability ratio was 13.17 percent, gross margin was 63.91 percent, return on equity was minus 1.09 percent, and diluted earnings per share was minus 0.10 yuan.

Impact on assets 1

Others▼ · 1 stocks
© 2026 MarketIVNews